CA
NZ
UK
AU
IND
US
Lineage Inc. (NASDAQ: LINE) witnessed a modest increase in its share price, rising 0.4% in pre-market trading as investors reevaluate the ongoing cyclical challenges facing the company. This uptick comes amid discussions in the marketplace surrounding the potential resilience of Lineage’s overall business strategy, …
Rafael Holdings, Inc. Is set to release a presentation document aimed at providing shareholders with updated insights into the company’s strategic outlook. The materials will include forward-looking statements that outline anticipated developments. The presentation will be published on the company’s investor relations website beginning …
Aimei Health Technology Co. Ltd. Has officially terminated its Business Combination Agreement with United Hydrogen Group Inc. Signaling a significant shift in its strategic plans. Initially entered on June 19, 2024, this deal aimed to consolidate the companies into a stronger market entity but …
ENDRA Life Sciences Inc. (NASDAQ: NDRA) has resolved a critical Nasdaq listing violation after its stockholders’ equity dipped below the required $2,500,000 threshold for the year ended December 31, 2025. The healthcare technology firm received formal notice on July 8, 2026, confirming its return …
A fact‑finding mission operating independently of any national government has issued a public appeal for the immediate release of a Palestinian medical professional held by Israeli authorities for an extended period. The call, emerging amid claims of mistreatment, has sharpened risk calculations across capital …
Prime Medicine (NASDAQ: PRME) experienced an immediate uptick in its share price after a court‑appointed arbitration panel ruled in the company’s favor against Beam Therapeutics. The decision, coupled with new backing from a prominent ARK investment fund, sparked renewed buying interest across biotech desks.
Biotechnology equities are drawing renewed attention after TD Cowen analysts spotlighted a standout stock in the sector, signaling potential for broader gains across healthcare. The move underscores shifting investor sentiment toward companies with promising drug pipelines and regulatory tailwinds, even as broader market volatility …
TransMedics Group, a medical technology company, saw its analyst price target reduced to $90 from $100 by Evercore ISI analyst Daniel Markowitz, who maintained an Outperform rating. The adjustment reflects the company’s ongoing efforts to broaden the adoption of its Organ Care System, which …
FibroBiologics (NASDAQ: FBLG) announced a change in its board composition, appointing Kathleen Rubins, Ph.D. As a director following the resignation of Matt Link. The appointment underscores the company’s commitment to integrating expertise in biomedical research and space-related scientific advancements into its governance structure.
Financially, the $30 million in committed financing tied to the transaction is designed to extend the combined company's cash runway into the second half of 2028, providing roughly two years of operating capital following the deal's close. That runway calculation matters enormously for how …
Please wait processing your request...